Table 1.

Lipid profile in control and rosuvastatin-treated rats four months after AAV treatment.

	Cholesterol (mg/dl)	HDL (mg/dl)	LDL (mg/dl)	Triglyceride (mg/dl)
Control	42.8 ± 2.0	18.0 ± 1.4	19.6 ± 1.8	28.0 ± 1.7
Control + Rosuvastatin	41.8 ± 1.4	18.4 ± 1.7	18.6 ± 0.9	27.2 ± 2.3
AAV-GFP	42.0 ± 2.3	19.0 ± 1.5	19.0 ± 1.3	27.0 ± 2.4
AAV-GFP + Rosuvastatin	42.2 ± 2.7	19.2 ± 2.1	19.6 ± 1.4	27.6 ± 2.4
AAV-hCRP	42.4 ± 3.2	17.0 ± 1.5	18.2 ± 1.0	29.0 ± 1.9
AAV-hCRP + Rosuvastatin	41.6 ± 2.1	16.6 ± 2.1	17.6 ± 1.5	28.4 ± 1.5

Plasma concentrations of total, LDL and HDL cholesterol, and triglycerides were determined four months after AAV-hCRP injection and two months after rosuvastatin treatment. Data are expressed as mean ± SEM (n=6 per group). There were no significant differences between the treatment groups.